Atara raises ~$36M via registered direct offering; appoints Gregory Ciongoli to board

Atara Biotherapeutics, Inc.

Registered direct offering of 758,900 shares and pre-funded warrants for up to 3,604,780 shares at $8.25/$8.2499.
Gross proceeds ~$36M; net proceeds for working capital and general corporate purposes.
Adiumentum Capital Fund I LP (Ciongoli is Managing Partner) purchases $7.5M of the offering.
Gregory A. Ciongoli appointed to Board of Directors effective upon closing on September 5, 2024.
Ciongoli is independent, not receiving director compensation; standard indemnification agreement.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gregory A. Ciongoli

member of the Board

ATRA · Atara Biotherapeutics, Inc.

Filed: September 3, 2024, 7:59 PM ET

On September 3, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed, effective as of and contingent upon the Closing Date (as defined below), Mr. Gregory A. Ciongoli to serve as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory A. Ciongoli was appointed as member of the Board at Atara Biotherapeutics, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

On September 3, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed, effective as of and contingent upon the Closing Date (as defined below), Mr. Gregory A. Ciongoli to serve as a member of the Board.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-212168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.